Beyond YBX1, we characterized the putative bipotent cells in terms of a 144-gene “bipotent” expression signature, which clearly marked basal breast cancer, and which also correlated with poor overall survival within the basal subtype independently of standard prognostic factors, all consistent with it defining a “poor outcome stemness signature”. This evidence concerns the gene YBX1 and breast cancer.